Oramed Pharmaceuticals (ORMP) Financials

Oramed Pharmaceuticals logo
$3.90 +0.19 (+5.12%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$3.90 0.00 (-0.13%)
As of 11/16/2026 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Oramed Pharmaceuticals

Annual Income Statements for Oramed Pharmaceuticals

This table shows Oramed Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 8/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-7.23 -11 -10 -13 -14 -12 -22 -37 4.65 -19 64
Consolidated Net Income / (Loss)
-7.23 -11 -10 -13 -14 -12 -23 -38 11 -19 64
Net Income / (Loss) Continuing Operations
-7.23 -11 -10 -13 -14 -12 -23 -38 5.09 -19 64
Total Pre-Tax Income
-7.23 -9.63 -10 -13 -14 -12 -23 -38 5.09 -16 75
Total Operating Income
-7.38 -10 -11 -14 -15 -12 -24 -41 -16 -13 -15
Total Gross Profit
0.00 0.64 2.27 2.54 2.61 2.71 2.70 0.85 1.63 0.00 0.01
Total Revenue
0.00 0.64 2.46 2.45 2.70 2.71 2.70 0.85 1.63 0.00 2.00
Operating Revenue
0.00 0.64 2.46 2.45 2.70 2.71 2.70 0.85 1.63 0.00 2.00
Total Cost of Revenue
0.00 0.00 0.19 -0.09 0.09 0.00 0.00 0.00 0.00 0.00 1.99
Operating Cost of Revenue
0.00 - 0.19 -0.09 0.09 - - - - 0.00 1.99
Total Operating Expenses
7.38 11 13 16 17 14 27 41 17 13 15
Selling, General & Admin Expense
2.60 2.45 2.76 4.08 3.72 4.23 5.94 14 8.43 6.46 8.72
Research & Development Expense
4.78 7.71 10 12 14 10 21 28 8.97 6.32 6.38
Total Other Income / (Expense), net
0.15 0.38 0.69 0.80 0.58 0.25 1.23 2.93 21 -3.14 90
Interest Expense
- - - - - - - 0.00 2.04 0.85 0.00
Other Income / (Expense), net
- - - - 0.58 -0.44 -0.01 2.93 23 -2.29 90
Income Tax Expense
-0.00 1.34 0.40 0.00 0.30 - - 0.10 0.00 3.18 11
Net Income / (Loss) Attributable to Noncontrolling Interest
- - - - - 0.00 -0.75 -1.20 0.44 -0.04 -0.03
Basic Earnings per Share
$0.67 $0.87 - - $0.82 $0.56 $0.78 ($0.94) $0.14 ($0.48) $1.53
Weighted Average Basic Shares Outstanding
10.82M 12.62M 13.31M 14.88M 17.45M 20.53M 38.09M 39.00M 40.32M 40.85M 41.40M
Diluted Earnings per Share
$0.67 $0.87 - - $0.82 $0.56 $0.78 ($0.94) $0.14 ($0.48) $1.50
Weighted Average Diluted Shares Outstanding
10.82M 12.62M 13.31M 14.88M 17.45M 20.53M 38.09M 39.00M 40.57M 40.85M 42.42M
Weighted Average Basic & Diluted Shares Outstanding
10.82M 12.62M 13.31M 14.88M 17.45M 20.53M 28.47M 39.78M 40.52M 40.85M 40.45M
Cash Dividends to Common per Share
- - - - - - - - - - $0.25

Quarterly Income Statements for Oramed Pharmaceuticals

This table shows Oramed Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
1.54 9.21 -20 -10 -7.64 13 48 10 38 78 18
Consolidated Net Income / (Loss)
1.53 9.20 -20 -10 -7.64 13 48 10 38 78 18
Net Income / (Loss) Continuing Operations
1.53 9.20 -20 -10 -7.64 13 48 10 38 78 18
Total Pre-Tax Income
1.53 11 -19 -9.78 -7.06 13 59 9.80 49 102 28
Total Operating Income
-2.96 -3.14 -3.09 -3.60 -4.50 -2.49 -2.43 -5.67 -3.66 -2.77 -4.10
Total Gross Profit
0.00 0.00 0.00 - 0.01 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 2.00 0.00 0.00 - 0.00 0.00 0.00
Operating Revenue
0.00 0.00 0.00 - 2.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 1.99 0.00 0.00 - 0.00 0.00 0.00
Operating Cost of Revenue
0.00 0.00 0.00 - 1.99 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
2.96 3.14 3.09 3.60 4.51 2.49 2.43 5.67 3.66 2.77 4.10
Selling, General & Admin Expense
1.78 1.69 0.85 2.13 2.31 1.46 1.27 3.68 2.07 2.77 4.10
Research & Development Expense
1.18 1.44 2.24 1.46 2.21 1.03 1.15 1.99 1.59 0.00 0.00
Total Other Income / (Expense), net
4.50 14 -15 -6.19 -2.56 16 62 15 53 104 32
Interest & Investment Income
- - - - - 16 62 - - - 32
Income Tax Expense
0.00 1.63 1.13 0.42 0.58 -0.13 11 -0.21 11 23 9.87
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.00 -0.01 -0.02 -0.01 - -0.03 -0.01 - - 0.00 0.00
Basic Earnings per Share
$0.04 $0.22 ($0.48) ($0.26) ($0.19) $0.32 $1.16 $0.24 $0.94 $1.90 $0.44
Weighted Average Basic Shares Outstanding
40.84M 40.96M 40.90M 40.85M 41.23M 41.74M 41.76M 41.40M 40.77M 41.04M 41.66M
Diluted Earnings per Share
$0.04 $0.22 ($0.48) ($0.26) ($0.19) $0.31 $1.13 $0.25 $0.91 $1.84 $0.43
Weighted Average Diluted Shares Outstanding
41.56M 41.59M 40.90M 40.85M 41.23M 42.61M 42.77M 42.42M 41.97M 42.50M 43.02M
Weighted Average Basic & Diluted Shares Outstanding
40.63M 40.77M 40.31M 0.00 40.85M 41.00M 39.80M 0.00 40.93M 41.60M 43.49M

Annual Cash Flow Statements for Oramed Pharmaceuticals

This table details how cash moves in and out of Oramed Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 8/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
1.45 0.69 0.06 1.03 -1.67 16 58 13 -31 45 -8.47
Net Cash From Operating Activities
-4.95 4.66 -5.83 -15 -13 -12 -21 -28 -10 -8.41 -9.15
Net Cash From Continuing Operating Activities
-4.95 4.66 -5.83 -15 -13 -12 -21 -28 -10 -8.41 -9.15
Net Income / (Loss) Continuing Operations
-7.23 -11 -10 -13 -14 -12 -23 -38 5.09 -19 64
Consolidated Net Income / (Loss)
-7.23 -11 -10 -13 -14 -12 -23 -38 5.09 -19 64
Depreciation Expense
0.00 0.00 0.01 0.01 0.01 0.01 0.08 0.06 0.20 0.19 0.12
Non-Cash Adjustments To Reconcile Net Income
1.77 0.57 1.77 1.67 1.12 2.22 3.05 11 -13 7.34 -79
Changes in Operating Assets and Liabilities, net
0.52 15 2.87 -3.60 0.29 -3.16 -1.32 -0.94 -2.70 3.16 5.89
Net Cash From Investing Activities
-3.31 -16 4.30 -7.00 11 4.63 -24 30 -73 106 5.44
Net Cash From Continuing Investing Activities
-3.31 -16 4.30 -7.00 11 4.63 -24 30 -73 106 5.44
Purchase of Property, Plant & Equipment
-0.00 -0.01 -0.01 -0.01 -0.02 -0.08 -0.38 -0.50 -0.25 -0.02 -0.01
Acquisitions
- - - - - - - - - 0.00 -7.00
Purchase of Investments
-23 -31 -25 -27 -31 -36 -54 -154 -191 -54 -23
Divestitures
- - - - - - - - - 0.00 6.25
Sale and/or Maturity of Investments
20 15 29 20 42 44 27 185 8.38 162 97
Other Investing Activities, net
-0.00 -0.00 -0.00 -0.00 -0.00 -3.75 3.76 0.00 110 -1.37 -68
Net Cash From Financing Activities
9.72 12 1.59 23 0.00 24 103 11 52 -52 -4.74
Net Cash From Continuing Financing Activities
9.72 12 1.59 23 0.00 24 103 11 52 -52 -4.74
Repayment of Debt
- - - - - - - 0.00 -50 -50 0.00
Repurchase of Common Equity
- - - - - - - - 0.00 -2.48 -4.74
Other Financing Activities, net
0.01 1.45 1.59 23 0.00 0.01 21 -0.72 0.00 -0.00 0.00
Cash Interest Received
0.12 0.26 0.83 0.83 - 1.31 - 1.84 5.16 7.38 4.63
Cash Income Taxes Paid
- - 0.40 0.00 0.30 - 0.56 0.10 - 2.32 0.00

Quarterly Cash Flow Statements for Oramed Pharmaceuticals

This table details how cash moves in and out of Oramed Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
9.52 66 -43 12 20 -59 36 -6.19 -33 2.04 14
Net Cash From Operating Activities
-1.48 2.08 -7.10 -1.91 -3.52 -3.54 -1.63 -0.47 -2.92 -0.20 0.43
Net Cash From Continuing Operating Activities
-1.48 2.08 -7.10 -1.91 -3.65 -3.54 -1.63 -0.47 -2.92 -0.20 0.43
Net Income / (Loss) Continuing Operations
1.53 9.20 -20 -10 -7.64 13 48 10 38 78 18
Consolidated Net Income / (Loss)
1.53 9.20 -20 -10 -7.64 13 48 10 38 78 18
Depreciation Expense
0.06 0.05 0.05 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Non-Cash Adjustments To Reconcile Net Income
-2.44 -9.36 11 8.29 5.54 -14 -60 -11 -49 -102 -27
Changes in Operating Assets and Liabilities, net
-0.63 2.18 1.63 -0.03 -1.58 -2.64 9.49 0.61 7.82 24 8.98
Net Cash From Investing Activities
30 95 -34 15 24 -55 38 -1.68 -19 4.31 13
Net Cash From Continuing Investing Activities
30 95 -34 15 24 -55 38 -1.68 -7.56 -7.61 13
Purchase of Property, Plant & Equipment
-0.00 - -0.01 -0.01 -0.00 -0.00 - -0.00 -0.01 -0.00 -0.00
Purchase of Investments
-4.00 - -38 -12 -1.19 6.25 -1.68 -19 -13 -21 8.21
Sale and/or Maturity of Investments
15 114 5.50 28 29 8.77 38 21 6.30 19 20
Other Investing Activities, net
19 -19 -1.31 -0.07 - -67 -0.75 -3.40 -1.00 -5.74 -15
Net Cash From Financing Activities
-19 -31 -1.29 -1.20 0.00 -0.37 -0.36 -4.01 -10 -1.95 0.04
Net Cash From Continuing Financing Activities
-19 -31 -1.29 -1.20 0.00 -0.37 -0.36 -4.01 -10 -1.95 0.04
Payment of Dividends
- - - - 0.00 - - - -10 -0.08 -0.06
Other Financing Activities, net
- - - - - - - - - - 0.10
Effect of Exchange Rate Changes
- - - - - - - - - - 0.03
Cash Interest Received
1.34 5.10 0.43 0.50 1.18 0.17 1.08 2.19 0.40 0.24 0.53
Cash Income Taxes Paid
- - - 2.32 - - -6.64 3.32 - - -0.00

Annual Balance Sheets for Oramed Pharmaceuticals

This table presents Oramed Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
26 43 39 47 35 45 178 162 221 155 231
Total Current Assets
17 31 20 31 33 41 148 157 163 143 133
Cash & Equivalents
3.21 3.91 3.97 5.00 3.33 19 27 40 9.06 54 46
Short-Term Investments
2.09 2.86 2.86 4.59 3.70 9.54 7.75 3.74 58 32 69
Accounts Receivable
- - - - - - - - - - 0.00
Prepaid Expenses
0.13 0.20 0.16 0.57 1.04 0.61 1.66 1.39 0.54 1.29 2.74
Other Current Assets
12 24 13 21 25 11 111 112 95 55 16
Plant, Property, & Equipment, net
0.01 0.02 0.02 0.02 0.02 0.10 0.39 0.82 0.87 0.70 0.59
Total Noncurrent Assets
8.97 12 18 16 1.32 4.02 29 3.72 57 11 97
Long-Term Investments
8.96 12 18 16 1.30 3.93 29 2.70 56 11 82
Other Noncurrent Operating Assets
- 0.01 0.01 0.02 0.02 0.09 0.53 1.02 0.73 0.45 15
Total Liabilities & Shareholders' Equity
26 43 39 47 35 45 178 162 221 155 231
Total Liabilities
1.53 17 19 16 15 12 11 10 58 9.93 31
Total Current Liabilities
1.49 3.62 5.17 4.55 5.31 4.54 7.37 5.75 53 5.69 19
Short-Term Debt
- - - - - 0.09 0.00 0.00 51 0.33 0.65
Accounts Payable
0.99 1.46 2.72 2.10 2.61 1.70 4.54 4.16 1.61 5.14 6.20
Dividends Payable
- - - - - - - - - 0.00 11
Current Deferred Revenue
0.50 2.16 2.45 2.45 2.70 2.70 2.70 1.34 - 0.00 1.35
Other Current Liabilities
- - - - 0.00 0.04 0.13 0.25 0.27 0.22 0.29
Total Noncurrent Liabilities
0.04 13 14 12 9.96 7.22 3.84 4.74 4.44 4.25 12
Noncurrent Deferred Revenue
0.00 13 14 11 9.66 - 3.34 4.00 4.00 4.00 2.00
Noncurrent Deferred & Payable Income Tax Liabilities
0.03 0.01 0.01 0.01 0.01 0.01 0.01 - 0.01 0.00 7.91
Noncurrent Employee Benefit Liabilities
0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.04
Other Noncurrent Operating Liabilities
0.00 0.39 0.44 0.31 0.27 0.24 0.47 0.72 0.41 0.22 2.08
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
25 26 19 31 19 33 167 151 163 145 200
Total Preferred & Common Equity
25 26 19 31 19 33 166 152 164 146 200
Total Common Equity
25 26 19 31 19 33 166 152 164 146 200
Common Stock
59 72 75 100 100 125 293 315 321 323 323
Retained Earnings
-35 -46 -56 -69 -81 -93 -127 -163 -158 -177 -123

Quarterly Balance Sheets for Oramed Pharmaceuticals

This table presents Oramed Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
231 204 184 165 148 162 220 269 370 401
Total Current Assets
176 177 153 143 131 99 136 68 53 57
Cash & Equivalents
5.47 19 85 42 75 16 52 13 15 29
Short-Term Investments
49 78 66 57 29 59 78 42 35 25
Accounts Receivable
- - - - - - - - 0.62 0.56
Prepaid Expenses
0.67 0.50 0.53 0.47 0.83 1.09 1.43 2.31 2.17 3.05
Other Current Assets
120 80 1.78 43 27 23 4.04 11 0.00 0.00
Plant, Property, & Equipment, net
0.92 0.82 0.77 0.72 0.67 0.65 0.61 0.56 0.53 0.51
Total Noncurrent Assets
54 26 30 22 14 62 84 200 316 343
Long-Term Investments
53 25 2.35 21 9.53 59 82 145 223 243
Other Noncurrent Operating Assets
0.77 0.64 28 0.52 4.64 3.45 1.90 55 93 100
Total Liabilities & Shareholders' Equity
231 204 184 165 148 162 220 269 370 401
Total Liabilities
83 38 8.07 9.56 7.65 8.10 18 31 52 62
Total Current Liabilities
78 34 3.73 5.27 5.49 3.69 6.12 11 11 9.45
Short-Term Debt
75 32 0.00 0.04 0.04 0.03 0.00 0.00 0.00 0.09
Accounts Payable
2.56 1.27 3.48 5.00 5.28 2.16 4.86 8.52 8.51 7.30
Dividends Payable
- - - - - - - 0.50 0.26 0.24
Current Deferred Revenue
0.00 - - - - 1.24 0.99 1.47 1.71 1.51
Other Current Liabilities
0.25 0.25 0.25 0.24 0.18 0.26 0.27 0.27 0.25 0.30
Total Noncurrent Liabilities
4.46 4.38 4.34 4.29 2.15 4.41 12 20 41 52
Noncurrent Deferred Revenue
4.00 4.00 4.00 4.00 2.00 3.72 3.50 1.53 0.00 0.00
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - - 7.92 18 41 50
Noncurrent Employee Benefit Liabilities
0.00 0.03 0.03 0.03 0.03 0.04 0.04 0.04 0.04 0.04
Other Noncurrent Operating Liabilities
0.46 0.35 0.31 0.26 0.12 0.65 0.59 0.49 0.64 2.21
Commitments & Contingencies
0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
148 166 176 156 140 154 202 238 317 339
Total Preferred & Common Equity
149 167 177 156 141 155 203 238 317 339
Total Common Equity
149 167 177 156 141 155 203 238 317 339
Common Stock
320 323 324 323 325 325 326 323 324 328
Retained Earnings
-171 -156 -147 -166 -184 -171 -123 -85 -6.97 11

Annual Metrics And Ratios for Oramed Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Oramed Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 8/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
11,550,846.00 13,136,658.00 13,320,962.00 17,362,615.00 17,383,359.00 23,526,812.00 32,514,145.00 39,114,736.00 40,338,979.00 40,312,069.00 40,312,069.00
DEI Adjusted Shares Outstanding
11,550,846.00 13,136,658.00 13,320,962.00 17,362,615.00 17,383,359.00 23,526,812.00 32,514,145.00 39,114,736.00 40,338,979.00 40,312,069.00 40,312,069.00
DEI Earnings Per Adjusted Shares Outstanding
-0.63 -0.83 -0.79 -0.73 -0.83 -0.49 -0.68 -0.93 0.12 -0.47 1.59
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 283.15% -0.29% 10.37% 0.26% -0.26% -68.48% 90.96% -100.00% 0.00%
EBITDA Growth
-25.07% -35.60% -7.60% -25.59% -3.89% 13.19% -98.08% -55.69% 119.47% -303.17% 607.23%
EBIT Growth
-25.01% -35.58% -7.60% -25.59% -3.90% 13.19% -98.60% -55.44% 118.92% -311.47% 599.93%
NOPAT Growth
-25.01% -35.58% -7.60% -25.59% -8.16% 19.64% -106.03% -67.60% 44.51% 43.26% -43.33%
Net Income Growth
-26.97% -51.60% 4.41% -21.44% -12.79% 19.81% -99.71% -64.27% 128.10% -280.00% 435.11%
EPS Growth
8.06% 29.85% 0.00% 0.00% 0.00% -31.71% 39.29% -220.51% 114.89% -442.86% 412.50%
Operating Cash Flow Growth
-21.58% 194.12% -225.26% -151.36% 11.71% 3.86% -70.27% -31.81% 63.12% 18.29% -8.71%
Free Cash Flow Firm Growth
113.03% -291.16% 246.36% -428.43% 22.00% 73.26% -2,505.03% 73.07% 91.35% 1,401.01% -38.72%
Invested Capital Growth
-41.28% -25.69% -176.41% 186.76% 112.95% -35.43% 1,333.50% 1.77% -12.62% -47.18% -70.00%
Revenue Q/Q Growth
0.00% 1,786.84% -2.42% -0.04% 2.43% 0.00% 0.00% -68.48% 95.32% 100.00% 0.00%
EBITDA Q/Q Growth
30.77% -2,197.69% 47.66% -2.24% 8.96% -10.09% -12.42% -3.05% 134.10% -257.60% 35.05%
EBIT Q/Q Growth
30.77% -2,211.81% 47.65% -2.24% 8.95% -10.07% -12.41% -3.07% 132.94% -263.36% 35.12%
NOPAT Q/Q Growth
30.77% -1,578.27% 47.65% -2.24% 33.65% -6.06% -12.37% -11.10% -4.14% 31.51% -25.41%
Net Income Q/Q Growth
11.39% -153.33% 36.62% -1.84% -2,733.95% 0.00% 0.00% -9.43% 162.64% -292.63% 45.99%
EPS Q/Q Growth
189.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -536.36% 51.52%
Operating Cash Flow Q/Q Growth
-4.81% 246.52% -293.08% -21.56% 9.64% 6.11% -29.49% -2.87% 39.22% -6.23% 13.64%
Free Cash Flow Firm Q/Q Growth
129.96% -442.55% 323.70% -249.21% 18.61% 74.52% -17,711.50% 78.46% 85.73% -49.40% -28.65%
Invested Capital Q/Q Growth
-11.35% -40.46% -480.32% 393.45% 327.63% -39.13% 3,867.49% -6.97% -20.96% 37.76% 418.61%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 100.00% 92.39% 103.51% 96.67% 100.00% 100.00% 100.00% 100.00% 0.00% 0.65%
EBITDA Margin
0.00% -1,561.00% -438.36% -552.10% -519.68% -449.96% -893.60% -4,413.85% 449.97% 0.00% 3,772.25%
Operating Margin
0.00% -1,561.62% -438.56% -552.35% -541.29% -433.84% -896.15% -4,765.02% -969.21% 0.00% -754.40%
EBIT Margin
0.00% -1,561.62% -438.56% -552.35% -519.98% -450.22% -896.45% -4,420.66% 437.92% 0.00% 3,766.20%
Profit (Net Income) Margin
0.00% -1,710.45% -426.71% -519.68% -531.08% -424.76% -850.50% -4,432.39% 652.30% 0.00% 3,200.80%
Tax Burden Percent
99.99% 113.86% 103.97% 100.00% 102.13% 100.00% 100.00% 100.27% 208.59% 119.99% 84.99%
Interest Burden Percent
97.97% 96.19% 93.58% 94.09% 100.00% 94.34% 94.87% 100.00% 71.41% 105.66% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15.01%
Return on Invested Capital (ROIC)
0.00% -76.21% -815.54% 0.00% -125.94% -90.37% -30.95% -27.50% -16.14% 0.00% -41.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -51.96% -802.05% 0.00% -101.92% -71.11% -17.53% -10.67% -60.60% 0.00% -95.39%
Return on Net Nonoperating Assets (RNNOA)
0.00% 33.23% 769.40% 0.00% 69.10% 46.33% 7.90% 3.73% 22.90% 0.00% 78.10%
Return on Equity (ROE)
-31.70% -42.98% -46.14% -50.55% -56.85% -44.04% -23.05% -23.77% 6.76% -12.39% 37.10%
Cash Return on Invested Capital (CROIC)
15.77% -46.74% 0.00% -397.46% -198.13% -47.32% -204.86% -29.25% -2.68% 48.90% 66.69%
Operating Return on Assets (OROA)
0.00% -28.94% -26.42% -31.42% -34.26% -30.77% -21.79% -22.19% 3.73% 0.00% 39.01%
Return on Assets (ROA)
0.00% -31.70% -25.70% -29.56% -34.99% -29.03% -20.67% -22.25% 5.55% 0.00% 33.16%
Return on Common Equity (ROCE)
-31.70% -42.98% -46.14% -50.55% -56.85% -44.04% -23.03% -23.81% 6.79% -12.47% 37.20%
Return on Equity Simple (ROE_SIMPLE)
-29.13% -41.86% -54.48% -40.91% -74.02% -35.01% -13.81% -24.88% 6.48% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-5.17 -7.01 -7.54 -9.47 -10 -8.23 -17 -28 -16 -8.95 -13
NOPAT Margin
0.00% -1,093.14% -306.99% -386.64% -378.90% -303.69% -627.31% -3,335.52% -969.21% 0.00% -641.15%
Net Nonoperating Expense Percent (NNEP)
-24.13% -24.25% -13.49% -12.74% -24.03% -19.27% -13.42% -16.83% 44.45% -12.02% 54.39%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -7.36% -6.14% -6.40%
Cost of Revenue to Revenue
0.00% 0.00% 7.61% -3.51% 3.33% 0.00% 0.00% 0.00% 0.00% 0.00% 99.35%
SG&A Expenses to Revenue
0.00% 382.53% 112.34% 166.72% 137.70% 156.16% 219.64% 1,621.01% 517.82% 0.00% 436.00%
R&D to Revenue
0.00% 1,202.65% 418.61% 489.14% 500.26% 377.68% 776.51% 3,244.01% 551.38% 0.00% 319.05%
Operating Expenses to Revenue
0.00% 1,661.62% 530.94% 655.86% 637.96% 533.84% 996.15% 4,865.02% 1,069.21% 0.00% 755.05%
Earnings before Interest and Taxes (EBIT)
-7.38 -10 -11 -14 -14 -12 -24 -38 7.13 -15 75
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.38 -10 -11 -14 -14 -12 -24 -38 7.32 -15 75
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.61 3.62 5.99 2.76 2.98 2.50 3.84 3.10 0.57 0.62 0.00
Price to Tangible Book Value (P/TBV)
2.61 3.62 5.99 2.76 2.98 2.50 3.84 3.10 0.57 0.62 0.00
Price to Revenue (P/Rev)
0.00 147.76 46.92 35.09 21.35 30.30 236.73 552.29 57.27 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20.04 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.99% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
4.80 9.74 0.00 11.55 4.46 7.89 5.62 4.06 0.22 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 119.13 36.64 24.51 18.27 20.80 213.05 496.47 12.57 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.79 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.87 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 16.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
22.53 0.00 14.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.32 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.38 -0.64 -0.96 -1.02 -0.68 -0.65 -0.45 -0.35 -0.38 -0.55 -0.82
Leverage Ratio
1.06 1.36 1.80 1.71 1.62 1.52 1.12 1.07 1.22 1.22 1.12
Compound Leverage Factor
1.03 1.30 1.68 1.61 1.62 1.43 1.06 1.07 0.87 1.29 1.12
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 17.63% 0.00% 0.00% 23.96% 0.23% 0.33%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.23% 0.00% 0.00% 23.96% 0.23% 0.33%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 17.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.09% -0.43% -0.43% -0.63% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 82.37% 99.91% 100.43% 76.47% 100.40% 99.67%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.58 0.00 0.00 7.01 -0.02 0.01
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 2.11 0.00 1.25 -9.81 6.54 -2.60
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.57 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.86 0.00 0.00 -3.26 -0.04 -0.05
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 3.13 0.00 1.65 4.55 10.87 15.30
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.84 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
23.46 1.93 1.12 0.90 -1.30 1.41 33.77 25.87 0.68 4.64 0.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.08% -0.16% -0.50% -0.60% -0.27%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
11.67 8.62 3.93 6.82 6.28 8.93 20.08 27.34 3.06 25.19 6.98
Quick Ratio
3.56 1.87 1.32 2.11 1.32 6.36 4.78 7.69 1.25 15.24 6.02
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2.25 -4.30 6.29 -21 -16 -4.31 -112 -30 -2.62 34 21
Operating Cash Flow to CapEx
-494,600.00% 51,722.22% -83,300.00% -293,140.00% -86,266.67% -15,170.73% -5,648.27% -5,914.83% -4,053.15% -46,733.33% -101,611.11%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.28 39.90 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.05 -9.86 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.18 -9.88 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.02 0.06 0.06 0.07 0.07 0.02 0.01 0.01 0.00 0.01
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 47.48 144.47 139.94 131.85 44.07 11.10 1.42 1.93 0.00 3.12
Accounts Payable Turnover
0.00 0.00 0.09 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.35
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 4,074.53 0.00 9,548.81 0.00 0.00 0.00 0.00 0.00 1,041.64
Cash Conversion Cycle (CCC)
0.00 0.00 -4,074.53 0.00 -9,548.81 0.00 0.00 0.00 0.00 0.00 -1,041.64
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
11 7.84 -5.99 5.20 11 7.15 102 104 91 48 14
Invested Capital Turnover
0.00 0.07 2.66 -6.18 0.33 0.30 0.05 0.01 0.02 0.00 0.06
Increase / (Decrease) in Invested Capital
-7.42 -2.71 -14 11 5.87 -3.92 95 1.81 -13 -43 -34
Enterprise Value (EV)
51 76 90 60 49 56 576 423 20 -7.20 0.00
Market Capitalization
65 95 115 86 58 82 640 471 93 91 0.00
Book Value per Share
$2.15 $1.99 $1.44 $1.79 $1.12 $1.40 $5.12 $3.88 $4.06 $3.63 $4.82
Tangible Book Value per Share
$2.15 $1.99 $1.44 $1.79 $1.12 $1.40 $5.12 $3.88 $4.06 $3.63 $4.82
Total Capital
25 26 19 31 19 40 167 151 214 146 200
Total Debt
0.00 0.00 0.00 0.00 0.00 7.04 0.00 0.00 51 0.33 0.65
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 6.95 0.00 0.00 0.00 0.00 0.00
Net Debt
-14 -18 -25 -26 -8.33 -26 -64 -47 -72 -97 -196
Capital Expenditures (CapEx)
0.00 0.01 0.01 0.01 0.02 0.08 0.38 0.47 0.25 0.02 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
11 21 8.29 17 21 7.23 105 107 94 51 -0.08
Debt-free Net Working Capital (DFNWC)
16 28 15 26 28 36 141 151 161 138 115
Net Working Capital (NWC)
16 28 15 26 28 36 141 151 109 138 114
Net Nonoperating Expense (NNE)
2.06 3.96 2.94 3.26 4.11 3.28 6.03 9.35 -26 10 -77
Net Nonoperating Obligations (NNO)
-14 -18 -25 -26 -8.33 -26 -64 -47 -72 -97 -185
Total Depreciation and Amortization (D&A)
0.00 0.00 0.01 0.01 0.01 0.01 0.08 0.06 0.20 0.19 0.12
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 3,249.77% 337.42% 689.91% 776.40% 266.61% 3,898.11% 12,577.11% 5,773.82% 0.00% -3.90%
Debt-free Net Working Capital to Revenue
0.00% 4,307.18% 616.12% 1,081.42% 1,036.48% 1,330.81% 5,200.48% 17,765.73% 9,877.57% 0.00% 5,741.85%
Net Working Capital to Revenue
0.00% 4,307.18% 616.12% 1,081.42% 1,036.48% 1,327.49% 5,200.48% 17,765.61% 6,722.19% 0.00% 5,709.25%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.67 $0.87 $0.79 $0.86 $0.00 $0.56 $0.78 $0.94 $0.14 ($0.48) $1.53
Adjusted Weighted Average Basic Shares Outstanding
11.60M 13.26M 14.31M 17.38M 17.40M 23.68M 38.09M 39.00M 40.32M 40.83M 41.40M
Adjusted Diluted Earnings per Share
$0.67 $0.87 $0.79 $0.86 $0.00 $0.56 $0.78 $0.00 $0.14 ($0.48) $1.50
Adjusted Weighted Average Diluted Shares Outstanding
11.60M 13.26M 14.31M 17.38M 17.40M 23.68M 38.09M 39.78M 40.57M 40.83M 42.42M
Adjusted Basic & Diluted Earnings per Share
$0.67 $0.87 $0.79 $0.86 $0.00 $0.56 $0.78 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
10.82M 12.62M 13.31M 14.88M 17.45M 20.53M 28.47M 39.78M 40.52M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-5.17 -7.01 -7.54 -9.47 -10 -8.23 -17 -28 -11 -8.95 -13
Normalized NOPAT Margin
0.00% -1,093.14% -306.99% -386.64% -378.90% -303.69% -627.31% -3,335.52% -678.45% 0.00% -641.15%
Pre Tax Income Margin
0.00% -1,502.18% -410.42% -519.68% -519.98% -424.76% -850.50% -4,420.66% 312.72% 0.00% 3,766.20%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.50 -17.66 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.74 -10.49 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.37 -17.68 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.87 -10.51 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13.00% 7.41%

Quarterly Metrics And Ratios for Oramed Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Oramed Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
40,338,979.00 40,628,924.00 40,769,027.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,926,081.00 41,597,354.00
DEI Adjusted Shares Outstanding
40,338,979.00 40,628,924.00 40,769,027.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,312,069.00 40,926,081.00 41,597,354.00
DEI Earnings Per Adjusted Shares Outstanding
0.04 0.23 -0.48 -0.25 -0.19 0.33 1.20 0.25 0.95 1.91 0.44
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Growth
161.05% 984.46% -667.76% -166.98% -422.09% 18.03% 422.27% 200.77% 803.90% 4,232.49% -70.03%
EBIT Growth
158.88% 945.32% -653.01% -167.44% -431.98% 18.34% 421.20% 200.14% 800.48% 4,181.44% -69.10%
NOPAT Growth
18.75% -0.33% -6.78% 35.09% -6.35% 5.61% 8.64% -130.27% 9.99% 15.32% -35.25%
Net Income Growth
142.48% 800.99% -498.11% -154.19% -598.17% 44.07% 346.35% 198.14% 601.31% 489.41% -61.95%
EPS Growth
150.00% 833.33% -500.00% -178.79% -575.00% 40.91% 335.42% 196.15% 578.95% 493.55% -61.95%
Operating Cash Flow Growth
73.40% 178.82% -923.20% -34.77% -138.41% -270.28% 77.12% 75.61% 17.16% 94.34% 126.22%
Free Cash Flow Firm Growth
268.59% 321.40% 1,600.12% 336.23% 11.95% -112.21% -52.04% -31.09% -17.49% -7,429.71% -227.88%
Invested Capital Growth
-36.94% -83.61% -69.69% -47.18% -65.35% 49.86% -112.97% -70.00% -156.50% 120.36% 515.67%
Revenue Q/Q Growth
100.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-85.01% 411.14% -265.49% 47.16% 27.93% 287.31% 351.85% -83.48% 403.41% 105.41% -104.01%
EBIT Q/Q Growth
-85.35% 422.06% -266.76% 47.14% 27.85% 286.09% 352.65% -83.52% 404.64% 105.48% -104.04%
NOPAT Q/Q Growth
23.60% 10.12% 18.78% -16.38% -25.17% 20.23% 21.39% -193.34% 51.07% 24.94% -25.55%
Net Income Q/Q Growth
-91.85% 500.00% -313.41% 48.08% 25.07% 273.51% 264.92% -79.32% 282.76% 104.01% -76.44%
EPS Q/Q Growth
-87.88% 450.00% -318.18% 45.83% 26.92% 263.16% 264.52% -77.88% 264.00% 102.20% -76.63%
Operating Cash Flow Q/Q Growth
-4.09% 240.65% -442.05% 73.09% -84.14% -0.45% 54.03% 71.32% -525.54% 93.14% 313.00%
Free Cash Flow Firm Q/Q Growth
350.15% 172.80% -31.39% -48.23% 15.52% -129.75% 369.53% -25.60% 38.31% -54.39% -110.70%
Invested Capital Q/Q Growth
-16.18% -70.07% 52.85% 37.76% -45.01% 29.43% -113.23% 418.61% -203.54% 11.87% -3.92%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% -351.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% -225.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% -352.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% -382.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 84.92% 106.12% 104.25% 108.27% 100.96% 81.39% 102.16% 77.49% 76.94% 65.10%
Interest Burden Percent
72.15% 97.65% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -689.08%
Effective Tax Rate
0.00% 15.08% 0.00% 0.00% 0.00% -0.96% 18.61% -2.16% 22.51% 23.07% 34.90%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -6.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -1.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 1.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% 0.00% 6.53% -12.39% -5.00% 0.00% 0.00% 0.00% 58.16% 74.24% 53.52%
Cash Return on Invested Capital (CROIC)
31.60% 127.82% 89.57% 48.90% 77.57% -73.44% 0.00% 66.69% 0.00% -111.17% -153.40%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% -4.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% -4.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% 0.00% 6.57% -12.47% -5.03% 0.00% 0.00% 0.00% 58.30% 74.39% 53.61%
Return on Equity Simple (ROE_SIMPLE)
9.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.96 -2.66 -2.16 -2.52 -3.15 -2.51 -1.98 -5.79 -2.84 -2.13 -2.67
NOPAT Margin
0.00% 0.00% 0.00% 0.00% -157.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
7.59% 14.42% -22.76% -9.09% -4.43% 11.57% 30.76% 11.19% 22.44% 39.45% 8.28%
Return On Investment Capital (ROIC_SIMPLE)
-1.50% -1.51% -1.39% -1.73% -2.25% -1.64% -0.98% -2.89% -1.19% -0.67% -0.79%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 99.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 115.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 110.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 225.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
2.13 11 -19 -9.78 -7.06 13 59 9.80 49 102 -4.10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2.18 11 -18 -9.75 -7.03 13 59 9.83 49 102 -4.07
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.71 0.59 0.64 0.62 0.57 0.00 0.00 0.00 0.00 0.62 0.57
Price to Tangible Book Value (P/TBV)
0.71 0.59 0.64 0.62 0.57 0.00 0.00 0.00 0.00 0.62 0.57
Price to Revenue (P/Rev)
122.57 363.82 0.00 0.00 40.21 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
12.29 5.22 27.70 0.00 0.00 0.00 0.00 0.00 0.00 1.13 1.34
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.35% 5.20% 5.35%
Earnings Yield
8.13% 19.14% 3.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 88.83% 74.58%
Enterprise Value to Invested Capital (EV/IC)
0.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
28.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
2.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
2.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.38 -0.50 -0.51 -0.55 -0.66 -0.83 -0.92 -0.82 -0.97 -0.86 -0.94
Leverage Ratio
1.15 1.04 1.30 1.22 1.15 1.05 1.08 1.12 1.10 1.13 1.15
Compound Leverage Factor
0.83 1.02 1.30 1.22 1.15 1.05 1.08 1.12 1.10 1.13 -7.91
Debt to Total Capital
16.20% 0.00% 0.02% 0.23% 0.03% 0.02% 0.00% 0.33% 0.00% 0.00% 0.03%
Short-Term Debt to Total Capital
16.20% 0.00% 0.02% 0.23% 0.03% 0.02% 0.00% 0.33% 0.00% 0.00% 0.03%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.46% -0.52% -0.59% -0.63% -0.66% -0.62% -0.47% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
84.27% 100.52% 100.57% 100.40% 100.63% 100.59% 100.47% 99.67% 100.00% 100.00% 99.97%
Debt to EBITDA
2.45 0.00 0.00 -0.02 0.00 0.00 0.00 0.01 0.00 0.00 -0.01
Net Debt to EBITDA
-6.83 0.00 -12.78 6.54 4.71 5.41 -3.70 -2.60 0.00 0.00 18.47
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-2.37 0.00 0.00 -0.04 0.00 0.00 0.00 -0.05 0.00 0.00 -0.01
Net Debt to NOPAT
6.61 0.00 9.23 10.87 11.32 12.47 20.23 15.30 0.00 0.00 23.93
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
1.68 7.82 5.46 4.76 5.44 0.00 0.00 0.00 0.00 3.28 2.03
Noncontrolling Interest Sharing Ratio
0.00% 0.00% -0.60% -0.60% -0.60% 0.00% 0.00% 0.00% -0.24% -0.20% -0.18%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.28 41.06 27.08 25.19 23.94 26.81 22.25 6.98 6.45 4.98 6.07
Quick Ratio
2.87 40.44 18.88 15.24 18.93 20.33 21.35 6.02 5.18 4.77 5.75
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
42 114 78 40 47 -14 37 28 39 -26 -55
Operating Cash Flow to CapEx
-73,800.00% 0.00% -142,020.00% -17,372.73% -117,300.00% -88,375.00% 0.00% -23,300.00% -58,300.00% -10,000.00% 10,650.00%
Free Cash Flow to Firm to Interest Expense
70.53 436.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-2.49 7.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-2.50 7.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
1.07 0.34 0.00 0.00 2.68 2.84 3.00 3.12 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.61 0.70 0.40 0.35 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 600.86 518.20 905.24 1,041.64 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 -600.86 -518.20 -905.24 -1,041.64 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
76 23 35 48 26 34 -4.53 14 -15 44 42
Invested Capital Turnover
0.01 0.00 0.00 0.00 0.04 0.07 0.13 0.06 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-45 -117 -80 -43 -50 11 -39 -34 -41 24 52
Enterprise Value (EV)
28 -50 -22 -7.20 -34 0.00 0.00 0.00 0.00 -77 -103
Market Capitalization
118 104 99 91 80 0.00 0.00 0.00 0.00 197 194
Book Value per Share
$4.08 $4.36 $3.84 $3.63 $3.42 $3.70 $4.87 $4.82 $5.84 $7.76 $8.15
Tangible Book Value per Share
$4.08 $4.36 $3.84 $3.63 $3.42 $3.70 $4.87 $4.82 $5.84 $7.76 $8.15
Total Capital
198 176 156 146 140 154 202 200 238 317 339
Total Debt
32 0.00 0.04 0.33 0.04 0.03 0.00 0.65 0.00 0.00 0.09
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-89 -153 -121 -97 -113 -119 -207 -196 -254 -274 -297
Capital Expenditures (CapEx)
0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
79 -1.42 38 51 22 20 -0.65 -0.08 2.84 -7.94 -5.74
Debt-free Net Working Capital (DFNWC)
176 150 138 138 126 95 130 115 58 43 48
Net Working Capital (NWC)
144 150 138 138 126 95 130 114 58 43 48
Net Nonoperating Expense (NNE)
-4.50 -12 17 7.68 4.49 -16 -50 -16 -41 -80 -21
Net Nonoperating Obligations (NNO)
-89 -153 -121 -97 -113 -119 -207 -185 -253 -273 -297
Total Depreciation and Amortization (D&A)
0.06 0.05 0.05 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Debt-free, Cash-free Net Working Capital to Revenue
8,248.18% -495.47% 0.00% 0.00% 1,103.85% 1,014.60% -32.50% -3.90% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
18,269.93% 52,103.48% 0.00% 0.00% 6,301.00% 4,768.35% 6,499.95% 5,741.85% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
14,936.42% 52,103.48% 0.00% 0.00% 6,299.20% 4,766.65% 6,499.90% 5,709.25% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.04 $0.22 ($0.48) ($0.26) ($0.19) $0.32 $1.16 $0.24 $0.94 $1.90 $0.44
Adjusted Weighted Average Basic Shares Outstanding
40.84M 40.96M 40.90M 40.85M 41.23M 41.74M 41.76M 41.40M 40.77M 41.04M 41.66M
Adjusted Diluted Earnings per Share
$0.04 $0.22 ($0.48) ($0.26) ($0.19) $0.31 $1.13 $0.25 $0.91 $1.84 $0.43
Adjusted Weighted Average Diluted Shares Outstanding
41.56M 41.59M 40.90M 40.85M 41.23M 42.61M 42.77M 42.42M 41.97M 42.50M 43.02M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
40.63M 40.77M 40.31M 0.00 40.85M 41.00M 39.80M 0.00 40.93M 41.60M 43.49M
Normalized Net Operating Profit after Tax (NOPAT)
-2.07 -2.66 -2.16 -2.52 -3.15 -1.74 -1.98 -3.97 -2.84 -2.13 -2.67
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% -157.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% -352.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
3.59 42.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-5.00 -10.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
3.59 42.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-5.01 -10.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 13.02% -13.00% 0.00% -11.81% 4.39% 7.41% 0.00% 2.50% 2.77%

Financials Breakdown Chart

Key Financial Trends

Oramed Pharmaceuticals’ (NASDAQ:ORMP) Q2 2026 statements show a company with substantial liquidity and no debt, but little evidence of an operating business generating recurring revenue. The company reported zero revenue in Q2, while net income reached $78.2 million. That profit was driven almost entirely by $104.4 million of other income rather than product sales or operating activities.

The balance sheet has expanded significantly. Total assets increased to $369.6 million in Q2 2026 from $161.7 million in Q2 2025, largely because long-term investments rose to $223.1 million from $58.6 million. However, the company’s investment-heavy balance sheet also makes reported earnings more dependent on market and transaction-related gains.

  • Strong liquidity: Oramed held $15.2 million in cash and $35.4 million in short-term investments at the end of Q2 2026. Including long-term investments, its investment portfolio totaled approximately $258.5 million.
  • No short-term debt: Short-term debt was zero in Q2 2026, compared with $75.4 million in Q3 2023 and $32.0 million in Q1 2024. Total liabilities were only $52.2 million against $317.5 million of equity.
  • Improved balance-sheet equity: Retained earnings improved to a deficit of $7.0 million in Q2 2026 from a deficit of $171.0 million in Q2 2025, reflecting significant recent reported gains.
  • Operating cash burn moderated: Net cash used in operating activities improved to $200,000 in Q2 2026 from $2.9 million in Q1 2026 and $3.5 million in Q2 2025. This suggests lower near-term cash consumption, although the company remains reliant on its investment portfolio.
  • Recent profitability: Oramed reported net income of $78.2 million in Q2 2026, following $38.3 million in Q1 2026, $10.0 million in Q4 2025 and $48.4 million in Q3 2025. Basic earnings per share rose to $1.90 in Q2 2026 from $0.94 in Q1.
  • Investment income is the primary earnings driver: Other income was $104.4 million in Q2 2026, compared with $53.1 million in Q1 2026 and $15.5 million in Q4 2025. These gains materially boosted earnings, but they may not be recurring or predictable.
  • Investment activity remains substantial: Oramed purchased $21.2 million of investments and received $19.3 million from investment sales or maturities during Q2 2026. The company also reported $4.3 million of total investing cash inflow, although the statement includes differences between continuing and total investing activity that investors should review in the filing.
  • No operating revenue in Q2 2026: Revenue has been zero in each of the reported quarters from Q2 2025 through Q2 2026, apart from $2.0 million in Q1 2025. Oramed continues to report operating losses because it has not established consistent commercial revenue.
  • Operating losses persist: Q2 2026 operating expenses were $2.8 million, producing an operating loss of $2.8 million despite the reported net profit. Research and development expense was recorded at zero in Q2, down from $1.6 million in Q1, which may reflect changes in development activity rather than improved operating performance.
  • Cash flow does not support reported earnings: Operating cash flow was negative in most of the reported quarters, including Q2 2026. The large gap between net income and operating cash flow reflects significant non-cash adjustments and reinforces that recent profits have not come from a cash-generating operating business.

Overall, Oramed’s financial position is well capitalized and relatively low risk from a debt perspective. However, the investment case remains dependent on the value of its investment portfolio and the possibility of future pharmaceutical revenue. Investors should distinguish between investment-related gains and sustainable operating growth, particularly because the company has continued to report zero or minimal revenue.

11/17/26 01:44 AM ETAI Generated. May Contain Errors.

Oramed Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Oramed Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Oramed Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $64.02 million in 2025, compared with -$7.23 million in 2015. The previous period was -$19.10 million in 2024. View Oramed Pharmaceuticals' forecast to see where analysts expect Oramed Pharmaceuticals to go next.

Oramed Pharmaceuticals' total operating income in 2025 was -$15.09 million, based on the following breakdown:
  • Total Gross Profit: $13 thousand
  • Total Operating Expenses: $15.10 million

Over the last 10 years, Oramed Pharmaceuticals' total revenue changed from $0.00 in 2015 to $2 million in 2025, a change of 200,000,000.0%.

In the past 12 quarters, Oramed Pharmaceuticals' cash and equivalents has ranged from $5.47 million in Q3 2023 to $84.75 million in Q2 2024, and is currently $28.93 million as of their latest financial filing in Q3 2026.

Oramed Pharmaceuticals had total debt of $652 thousand at the end of 2025, a 98.2% increase from 2024, and none in 2015.

Over the last 10 years, Oramed Pharmaceuticals' book value per share changed from 2.15 in 2015 to 4.82 in 2025, a change of 124.4%.



Financial statements for NASDAQ:ORMP last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners